article thumbnail

Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China

The Pharma Data

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

Normality sensing licenses local T cells for innate-like tissue surveillance. Science 294(5542):605-609 (2001). Kabelitz D, Serrano R, Kouakanou L, et al. Cancer immunotherapy with γδ T cells: many paths ahead of us. Cell Mol Immunol 17:925-939 (2020). McKenzie D, Hart R, Bah N, et al. Nat Immunol 23:411-422 (2022).

Therapies 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Manitoba Judge’s Opinion Reveals Different Side of the CanadaDrugs Case

Policy Prescription

The crux of the Manitoba court’s decision is that CanadaDrugs’ founder and CEO, Kris Thorkelson , gets his pharmacist license back after it was revoked in 2019. The Winnipeg Free Press has an excellent story on that. Kris Thorkelson never pled guilty to selling counterfeit drugs. clinics in 2011.

article thumbnail

Article EMA Thank You New MHRA Windsor Framework documents guide post-Brexit flow of medicines for U.K., Great Britain, and the E.U.

Agency IQ

The document specifically notes that it applies to “medicinal products for human use intended to be placed on the market in Northern Ireland in accordance with Article 6 of Directive 2001/83/EC,” the current European pharmaceutical legislation. However, labeling requirements depend on the type of license of the medicine. member state.

article thumbnail

Landiolol

New Drug Approvals

The synthesis of 3 in high yields starting from 15 and 19 is described in CN100506814. . “Landiolol: An Ultra-Short-Acting -Blocker” Cardiology in Review. 32 (5): 468472. doi : 10.1097/CRD.0000000000000555. 0000000000000555. PMID 37185629.

FDA 62
article thumbnail

Article FDA Thank You The FDA rejected a psychedelic sponsor’s bid for approval. Here are six industry takeaways

Agency IQ

The June 2023 guidance recommends that studies involve two monitors (one with graduate-level professional training and clinical experience in psychotherapy, licensed to practice independently) to observe study participants during treatment sessions. Lykos (formerly MAPS PBC) met with the agency in 2016 for the End of Phase 2 meeting.

FDA 40
article thumbnail

DARPA Neurotechnology: The Deep Dive

Codon

The grant doled out funds to non-neurotechnology projects, too, but the Nicolelis, Andersen, and Donoghue papers were presumably so exciting that DARPA decided to launch an expanded program in 2001. They called it, simply, “Brain Machine Interfaces.”